Physician profile
Jason Kinzel
NPI 1558577452
$9,826.38
in general payments reported to CMS, 2019-2025
37 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $194 · 2021: $1,069 · 2022: $2,337 · 2023: $1,561 · 2024: $1,738 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.77 |
| Education | $124.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,368.14 | 2019-2025 | |
| Janssen Biotech, INC. | $1,182.62 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $984.31 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $864.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $567.23 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $488.48 | 2019-2025 | |
| Qol Medical, LLC | $337.27 | 2021-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $201.98 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $166.39 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $163.82 | 2025 | Rezdiffra |
| Allergan, INC. | $140.10 | 2019 | |
| Ardelyx, INC. | $136.52 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $127.20 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $123.86 | 2020-2022 | |
| Ucb, INC. | $117.55 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $94.05 | 2022-2025 | Gimoti |
| Merck Sharp & Dohme LLC | $87.33 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $79.41 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $76.55 | 2019-2024 | Sutab, Suflave |
| Celgene Corporation | $68.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $49.15 | 2022-2025 | Dupixent |
| Genzyme Corporation | $45.80 | 2022-2025 | |
| Celltrion USA INC. | $40.04 | 2024 | Zymfentra |
| Exact Sciences Corporation | $39.92 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $38.52 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $33.63 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $26.96 | 2023 | Idacio |
| Orphalan INC | $25.34 | 2024 | Cuvrior |
| Mylan Institutional INC. | $23.78 | 2023 | Hulio |
| Novo Nordisk INC | $22.54 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $17.68 | 2019 | |
| Boston Scientific Corporation | $17.31 | 2021 | |
| Axonics, INC. | $15.28 | 2024 | Axonics |
| Nestle Healthcare Nutrition INC. | $13.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2022 | |
| Intra-Sana Laboratories | $13.50 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shire North American Group INC | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kinzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.